Trial Outcomes & Findings for A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation (NCT NCT01682863)

NCT ID: NCT01682863

Last Updated: 2016-03-30

Results Overview

The overall rate of adverse events reported from initiation through 30 days post last dose.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

614 participants

Primary outcome timeframe

56 weeks

Results posted on

2016-03-30

Participant Flow

Patients were randomized to each treatment arm in 1:1:1 ratio.

Six hundred fifteen patients were randomized. One patient was randomized but did not receive treatment due to an adverse event. In the safety set, patients were analyzed according to the treatment received. Therefore, protocol enrollment and analysis set was 614 but the participant flow was 615

Participant milestones

Participant milestones
Measure
QVA149 27.5/12.5 ug Bid
QVA149 27.5/25 ug Bid
QAB149 75 ug od
Overall Study
STARTED
204
204
207
Overall Study
Safety Set
204
204
206
Overall Study
Full Analysis Set (FAS)
204
204
206
Overall Study
Randomized Set
204
204
207
Overall Study
COMPLETED
177
187
183
Overall Study
NOT COMPLETED
27
17
24

Reasons for withdrawal

Reasons for withdrawal
Measure
QVA149 27.5/12.5 ug Bid
QVA149 27.5/25 ug Bid
QAB149 75 ug od
Overall Study
Subject/guardian decision
19
12
10
Overall Study
Lost to Follow-up
5
1
6
Overall Study
Death
1
3
4
Overall Study
Protocol deviation
1
0
1
Overall Study
Technical problems
1
0
0
Overall Study
Adverse Event
0
1
2
Overall Study
Physician Decision
0
0
1

Baseline Characteristics

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
QVA149 27.5/12.5 ug Bid
n=204 Participants
QVA149 27.5/25 ug Bid
n=204 Participants
QAB149 75 ug od
n=207 Participants
Total
n=615 Participants
Total of all reporting groups
Age, Continuous
64.0 Years
STANDARD_DEVIATION 7.90 • n=5 Participants
63.9 Years
STANDARD_DEVIATION 8.50 • n=7 Participants
62.8 Years
STANDARD_DEVIATION 8.52 • n=5 Participants
63.6 Years
STANDARD_DEVIATION 8.32 • n=4 Participants
Sex: Female, Male
Female
73 Participants
n=5 Participants
81 Participants
n=7 Participants
58 Participants
n=5 Participants
212 Participants
n=4 Participants
Sex: Female, Male
Male
131 Participants
n=5 Participants
123 Participants
n=7 Participants
149 Participants
n=5 Participants
403 Participants
n=4 Participants

PRIMARY outcome

Timeframe: 56 weeks

Population: The Safety set:all patients that received at least one dose of study medication and had at least one post-baseline safety assessment. Patients were analyzed according to treatment received. The statement that a patient had no AEs also constituted a safety assessment. Only deaths occurring on treatment + 30 days after end of treatment were included.

The overall rate of adverse events reported from initiation through 30 days post last dose.

Outcome measures

Outcome measures
Measure
QVA149 27.5/12.5 ug Bid
n=204 Participants
QVA149 27.5/25 ug Bid
n=204 Participants
QAB149 75 ug od
n=206 Participants
Number of Patients With Adverse Events, Serious Adverse Events, and Death
Patients with at least one SAEs
26 Number of Patients
25 Number of Patients
24 Number of Patients
Number of Patients With Adverse Events, Serious Adverse Events, and Death
Patients with at least one AE
139 Number of Patients
142 Number of Patients
139 Number of Patients
Number of Patients With Adverse Events, Serious Adverse Events, and Death
Death
1 Number of Patients
3 Number of Patients
5 Number of Patients

SECONDARY outcome

Timeframe: 56 weeks

Population: The Safety set consisted of all patients that received at least one dose of study medication and had at least one post-baseline safety assessment. Patients were analyzed according to treatment received.

methodTime to premature treatment discontinuation for each treatment group was displayed using a Kaplan-Meier curve. The date of last dose of study medication was considered as the event date and also as the censoring date for those patients who did not discontinue treatment earl

Outcome measures

Outcome measures
Measure
QVA149 27.5/12.5 ug Bid
n=204 Participants
QVA149 27.5/25 ug Bid
n=204 Participants
QAB149 75 ug od
n=206 Participants
Time to Premature Discontinuation of Treatment
384.0 Days
95% Confidence Interval 0.164 • Interval 384.0 to
NA- Not estimable
NA Days
95% Confidence Interval 0.164
NA- Not estimable
NA Days
95% Confidence Interval 0.166
NA- Not estimable

SECONDARY outcome

Timeframe: Day 29, 57,, 85, 141, 197, 253, 309 and 365

Population: The Full Analysis set (FAS) included all randomized patients who received at least one dose of study medication. Participants, who had both baseline and week 52 values, were included in the analysis. Patients were analyzed according to the treatment to which they were randomized.

Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FEV1 was defined as the average of the pre-dose FEV1 measured at -45 minutes (min) and -15 min at day 1. A mixed model for repeated measures (MMRM), used for this analysis, included terms of treatment, baseline FEV1 measurements, smoking status at baseline, baseline inhaled corticosteroid (ICS) use, region, baseline FEV1 \* visit interaction, and visit, treatment \* visit interaction.

Outcome measures

Outcome measures
Measure
QVA149 27.5/12.5 ug Bid
n=192 Participants
QVA149 27.5/25 ug Bid
n=196 Participants
QAB149 75 ug od
n=199 Participants
Change From Baseline in Pre-dose Trough FEV1
Day 197
0.138 Liters
Standard Error 0.0167
0.181 Liters
Standard Error 0.0165
0.079 Liters
Standard Error 0.0166
Change From Baseline in Pre-dose Trough FEV1
Day 253
0.142 Liters
Standard Error 0.0168
0.153 Liters
Standard Error 0.0165
0.074 Liters
Standard Error 0.0167
Change From Baseline in Pre-dose Trough FEV1
Day 309
0.096 Liters
Standard Error 0.0162
0.123 Liters
Standard Error 0.0161
0.050 Liters
Standard Error 0.0162
Change From Baseline in Pre-dose Trough FEV1
Day 29
0.164 Liters
Standard Error 0.0144
0.194 Liters
Standard Error 0.0143
0.109 Liters
Standard Error 0.0143
Change From Baseline in Pre-dose Trough FEV1
Day 57
0.178 Liters
Standard Error 0.0151
0.199 Liters
Standard Error 0.0149
0.107 Liters
Standard Error 0.0149
Change From Baseline in Pre-dose Trough FEV1
Day 85
0.166 Liters
Standard Error 0.0158
0.201 Liters
Standard Error 0.0157
0.095 Liters
Standard Error 0.0157
Change From Baseline in Pre-dose Trough FEV1
Day 141
0.174 Liters
Standard Error 0.0173
0.198 Liters
Standard Error 0.0170
0.087 Liters
Standard Error 0.0171
Change From Baseline in Pre-dose Trough FEV1
Day 365
0.116 Liters
Standard Error 0.0169
0.116 Liters
Standard Error 0.0167
0.037 Liters
Standard Error 0.0169

SECONDARY outcome

Timeframe: Day 1, 29, 57, 85, 141, 197, 253, 309, and 365

Population: The Full Analysis set (FAS) included all randomized patients who received at least one dose of study medication. Participants, who had both baseline and week 52 values, were included in the analysis. Patients were analyzed according to the treatment to which they were randomized.

Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FEV1 was defined as the average of the pre-dose FEV1 measured at -45 minutes (min) and -15 min at day 1. A mixed model for repeated measures (MMRM), used for this analysis, included terms of treatment, baseline FEV1 measurements, smoking status at baseline, baseline inhaled corticosteroid (ICS) use, region, baseline FEV1 \* visit interaction, and visit, treatment \* visit interaction.

Outcome measures

Outcome measures
Measure
QVA149 27.5/12.5 ug Bid
n=200 Participants
QVA149 27.5/25 ug Bid
n=202 Participants
QAB149 75 ug od
n=202 Participants
Change From Baseline in 1 Hour Post-dose FEV1 Measurements
Day 1
0.166 Liters
Standard Error 0.0088
0.178 Liters
Standard Error 0.0088
0.122 Liters
Standard Error 0.0089
Change From Baseline in 1 Hour Post-dose FEV1 Measurements
Day 29
0.257 Liters
Standard Error 0.0152
0.287 Liters
Standard Error 0.0151
0.173 Liters
Standard Error 0.0151
Change From Baseline in 1 Hour Post-dose FEV1 Measurements
Day 57
0.267 Liters
Standard Error 0.0157
0.302 Liters
Standard Error 0.0155
0.173 Liters
Standard Error 0.0154
Change From Baseline in 1 Hour Post-dose FEV1 Measurements
Day 85
0.269 Liters
Standard Error 0.0164
0.301 Liters
Standard Error 0.0162
0.170 Liters
Standard Error 0.0162
Change From Baseline in 1 Hour Post-dose FEV1 Measurements
Day 141
0.268 Liters
Standard Error 0.0182
0.288 Liters
Standard Error 0.0179
0.170 Liters
Standard Error 0.0181
Change From Baseline in 1 Hour Post-dose FEV1 Measurements
Day 197
0.229 Liters
Standard Error 0.0178
0.278 Liters
Standard Error 0.0175
0.157 Liters
Standard Error 0.0177
Change From Baseline in 1 Hour Post-dose FEV1 Measurements
Day 253
0.231 Liters
Standard Error 0.0178
0.240 Liters
Standard Error 0.0175
0.140 Liters
Standard Error 0.0176
Change From Baseline in 1 Hour Post-dose FEV1 Measurements
Day 309
0.199 Liters
Standard Error 0.0170
0.222 Liters
Standard Error 0.0169
0.125 Liters
Standard Error 0.0170
Change From Baseline in 1 Hour Post-dose FEV1 Measurements
Day 365
0.212 Liters
Standard Error 0.0175
0.221 Liters
Standard Error 0.0173
0.104 Liters
Standard Error 0.0174

SECONDARY outcome

Timeframe: Day1, 29, 57, 85, 141, 197, 253, 309, and 365

Population: The Full Analysis set (FAS) included all randomized patients who received at least one dose of study medication. Participants, who had both baseline and week 52 values, were included in the analysis. Patients were analyzed according to the treatment to which they were randomized.

Pulmonary function assessments were performed using centralized spirometry according to international standards.

Outcome measures

Outcome measures
Measure
QVA149 27.5/12.5 ug Bid
n=200 Participants
QVA149 27.5/25 ug Bid
n=202 Participants
QAB149 75 ug od
n=202 Participants
Change From Baseline in FVC Measurement at All Post-baseline Time Points
Day 1
0.316 Liters
Standard Error 0.0201
0.349 Liters
Standard Error 0.0200
0.248 Liters
Standard Error 0.0203
Change From Baseline in FVC Measurement at All Post-baseline Time Points
Day 29
0.375 Liters
Standard Error 0.0274
0.440 Liters
Standard Error 0.0271
0.280 Liters
Standard Error 0.0272
Change From Baseline in FVC Measurement at All Post-baseline Time Points
Day 57
0.390 Liters
Standard Error 0.0274
0.439 Liters
Standard Error 0.0271
0.279 Liters
Standard Error 0.0271
Change From Baseline in FVC Measurement at All Post-baseline Time Points
Day 85
0.388 Liters
Standard Error 0.0287
0.432 Liters
Standard Error 0.0283
0.268 Liters
Standard Error 0.0284
Change From Baseline in FVC Measurement at All Post-baseline Time Points
Day 141
0.382 Liters
Standard Error 0.0297
0.403 Liters
Standard Error 0.0292
0.235 Liters
Standard Error 0.0295
Change From Baseline in FVC Measurement at All Post-baseline Time Points
Day 197
0.313 Liters
Standard Error 0.0288
0.400 Liters
Standard Error 0.0284
0.220 Liters
Standard Error 0.0288
Change From Baseline in FVC Measurement at All Post-baseline Time Points
Day 253
0.310 Liters
Standard Error 0.0303
0.365 Liters
Standard Error 0.0298
0.205 Liters
Standard Error 0.0301
Change From Baseline in FVC Measurement at All Post-baseline Time Points
Day 309
0.272 Liters
Standard Error 0.0284
0.334 Liters
Standard Error 0.0281
0.185 Liters
Standard Error 0.0285
Change From Baseline in FVC Measurement at All Post-baseline Time Points
Day 365
0.312 Liters
Standard Error 0.0286
0.323 Liters
Standard Error 0.0282
0.139 Liters
Standard Error 0.0286

SECONDARY outcome

Timeframe: 52 weeks

Population: The Full Analysis set (FAS) included all randomized patients who received at least one dose of study medication. Participants, who had both baseline and week 52 values, were included in the analysis.

Percentage of participants experiencing moderate or severe Chronic Obstructive Pulmonary Disease (COPD)

Outcome measures

Outcome measures
Measure
QVA149 27.5/12.5 ug Bid
n=204 Participants
QVA149 27.5/25 ug Bid
n=204 Participants
QAB149 75 ug od
n=206 Participants
Percentage of Participants Experiencing Moderate or Severe COPD Exacerbation
23.5 Percentage of participants
24.9 Percentage of participants
27.0 Percentage of participants

SECONDARY outcome

Timeframe: 52 weeks

Population: The Full Analysis set (FAS) included all randomized patients who received at least one dose of study medication. Participants, who had both baseline and week 52 values, were included in the analysis. Patients were analyzed according to the treatment to which they were randomized.

The participant recorded symptom scores twice daily in the eDiary. The daily clinical symptoms included: cough, wheezing, shortness of breath, sputum volume, sputum color, and night time awakening. The range of scores for each assessment is 0 to 3 where 0 indications No symptom and 3 indicates a Severe symptom. The maximum daytime total score is 27 and the maximum nighttime total score is 27. The total daily symptom score is obtained by adding the scores for the morning and evening symptoms for each day. The maximum possible total daily score is 54. A negative change from baseline indicated improvement.

Outcome measures

Outcome measures
Measure
QVA149 27.5/12.5 ug Bid
n=198 Participants
QVA149 27.5/25 ug Bid
n=199 Participants
QAB149 75 ug od
n=198 Participants
Change From Baseline in Mean Total Daily Symptom Scores
-1.57 Score on a scale
Standard Error 0.133
-1.56 Score on a scale
Standard Error 0.133
-1.31 Score on a scale
Standard Error 0.135

SECONDARY outcome

Timeframe: 52 weeks

Population: The Full Analysis set (FAS) included all randomized patients who received at least one dose of study medication. Participants, who had both baseline and week 52 values, were included in the analysis. Patients were analyzed according to the treatment to which they were randomized.

Participants completed an electronic diary (eDiary) twice daily at the same time in the morning and evening to record the number of puffs of rescue medication taken in the previous 12 hours.

Outcome measures

Outcome measures
Measure
QVA149 27.5/12.5 ug Bid
n=198 Participants
QVA149 27.5/25 ug Bid
n=199 Participants
QAB149 75 ug od
n=198 Participants
Change From Baseline in the Daily Number of Puffs of Rescue Medication Over the 52 Week Period
-1.89 Number of puffs
Standard Error 0.164
-1.62 Number of puffs
Standard Error 0.164
-1.73 Number of puffs
Standard Error 0.166

Adverse Events

QVA149 27.5/12.5 ug Bid

Serious events: 26 serious events
Other events: 118 other events
Deaths: 0 deaths

QVA149 27.5/25 ug Bid

Serious events: 25 serious events
Other events: 117 other events
Deaths: 0 deaths

QAB75

Serious events: 24 serious events
Other events: 112 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
QVA149 27.5/12.5 ug Bid
n=204 participants at risk
QVA149 27.5/25 ug Bid
n=204 participants at risk
QAB75
n=206 participants at risk
QVA149 27.5/25 μg capsules
Cardiac disorders
BRADYCARDIA
0.00%
0/204
0.49%
1/204
0.00%
0/206
Cardiac disorders
CARDIAC FAILURE
0.00%
0/204
0.49%
1/204
0.49%
1/206
Cardiac disorders
CARDIAC FAILURE ACUTE
0.00%
0/204
0.49%
1/204
0.00%
0/206
Cardiac disorders
CARDIAC TAMPONADE
0.00%
0/204
0.00%
0/204
0.49%
1/206
Blood and lymphatic system disorders
ANAEMIA
0.49%
1/204
0.00%
0/204
0.00%
0/206
Cardiac disorders
ACUTE MYOCARDIAL INFARCTION
0.98%
2/204
0.00%
0/204
0.00%
0/206
Cardiac disorders
ANGINA UNSTABLE
0.00%
0/204
0.49%
1/204
0.00%
0/206
Cardiac disorders
ATRIAL FIBRILLATION
0.49%
1/204
0.49%
1/204
0.00%
0/206
Cardiac disorders
ATRIAL FLUTTER
0.00%
0/204
0.00%
0/204
0.49%
1/206
Cardiac disorders
ATRIOVENTRICULAR BLOCK SECOND DEGREE
0.00%
0/204
0.49%
1/204
0.00%
0/206
Cardiac disorders
CARDIO-RESPIRATORY ARREST
0.00%
0/204
0.49%
1/204
0.49%
1/206
Cardiac disorders
CARDIOGENIC SHOCK
0.00%
0/204
0.49%
1/204
0.00%
0/206
Cardiac disorders
CORONARY ARTERY OCCLUSION
0.49%
1/204
0.00%
0/204
0.00%
0/206
Cardiac disorders
MYOCARDIAL INFARCTION
0.00%
0/204
0.49%
1/204
0.00%
0/206
Cardiac disorders
MYOCARDIAL ISCHAEMIA
0.00%
0/204
0.49%
1/204
0.00%
0/206
Cardiac disorders
PERICARDIAL EFFUSION
0.49%
1/204
0.00%
0/204
0.00%
0/206
Cardiac disorders
SILENT MYOCARDIAL INFARCTION
0.00%
0/204
0.49%
1/204
0.00%
0/206
Congenital, familial and genetic disorders
ASPLENIA
0.49%
1/204
0.00%
0/204
0.00%
0/206
Gastrointestinal disorders
ABDOMINAL PAIN
0.00%
0/204
0.49%
1/204
0.00%
0/206
Gastrointestinal disorders
HIATUS HERNIA
0.00%
0/204
0.00%
0/204
0.49%
1/206
Gastrointestinal disorders
INGUINAL HERNIA
0.00%
0/204
0.00%
0/204
0.49%
1/206
Gastrointestinal disorders
INGUINAL HERNIA STRANGULATED
0.00%
0/204
0.49%
1/204
0.00%
0/206
Gastrointestinal disorders
INTESTINAL OBSTRUCTION
0.00%
0/204
0.00%
0/204
0.49%
1/206
Gastrointestinal disorders
LARGE INTESTINE PERFORATION
0.00%
0/204
0.49%
1/204
0.00%
0/206
Gastrointestinal disorders
ORAL PAIN
0.00%
0/204
0.00%
0/204
0.49%
1/206
General disorders
FACIAL PAIN
0.00%
0/204
0.00%
0/204
0.49%
1/206
General disorders
NON-CARDIAC CHEST PAIN
0.00%
0/204
0.00%
0/204
0.49%
1/206
Infections and infestations
ARTHRITIS INFECTIVE
0.00%
0/204
0.00%
0/204
0.49%
1/206
Infections and infestations
BRONCHITIS
0.49%
1/204
0.00%
0/204
0.00%
0/206
Infections and infestations
BRONCHOPNEUMONIA
0.00%
0/204
0.00%
0/204
0.49%
1/206
Infections and infestations
DIVERTICULITIS
0.00%
0/204
0.49%
1/204
0.00%
0/206
Infections and infestations
ERYSIPELAS
0.00%
0/204
0.49%
1/204
0.00%
0/206
Infections and infestations
H1N1 INFLUENZA
0.00%
0/204
0.49%
1/204
0.00%
0/206
Infections and infestations
LOWER RESPIRATORY TRACT INFECTION
0.49%
1/204
0.49%
1/204
0.00%
0/206
Infections and infestations
LUNG INFECTION
0.00%
0/204
0.00%
0/204
0.49%
1/206
Infections and infestations
MENINGITIS
0.00%
0/204
0.49%
1/204
0.00%
0/206
Infections and infestations
PNEUMONIA
2.0%
4/204
0.49%
1/204
0.97%
2/206
Infections and infestations
PYELONEPHRITIS
0.49%
1/204
0.00%
0/204
0.00%
0/206
Infections and infestations
PYELONEPHRITIS ACUTE
0.49%
1/204
0.00%
0/204
0.00%
0/206
Infections and infestations
SEPSIS
0.49%
1/204
0.00%
0/204
0.00%
0/206
Infections and infestations
SINUSITIS
0.00%
0/204
0.49%
1/204
0.00%
0/206
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION BACTERIAL
0.98%
2/204
0.00%
0/204
0.00%
0/206
Infections and infestations
URINARY TRACT INFECTION
0.49%
1/204
0.00%
0/204
0.00%
0/206
Injury, poisoning and procedural complications
BRAIN HERNIATION
0.00%
0/204
0.49%
1/204
0.00%
0/206
Injury, poisoning and procedural complications
RIB FRACTURE
0.49%
1/204
0.00%
0/204
0.00%
0/206
Injury, poisoning and procedural complications
SKULL FRACTURED BASE
0.00%
0/204
0.49%
1/204
0.00%
0/206
Injury, poisoning and procedural complications
SUBDURAL HAEMORRHAGE
0.00%
0/204
0.49%
1/204
0.00%
0/206
Metabolism and nutrition disorders
DEHYDRATION
0.49%
1/204
0.00%
0/204
0.00%
0/206
Metabolism and nutrition disorders
HYPERGLYCAEMIA
0.49%
1/204
0.00%
0/204
0.00%
0/206
Metabolism and nutrition disorders
HYPOGLYCAEMIA
0.49%
1/204
0.00%
0/204
0.00%
0/206
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC PROTRUSION
0.00%
0/204
0.00%
0/204
0.49%
1/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOCARCINOMA OF COLON
0.00%
0/204
0.00%
0/204
0.49%
1/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BONE CANCER
0.00%
0/204
0.00%
0/204
0.49%
1/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
COLON CANCER
0.49%
1/204
0.00%
0/204
0.49%
1/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
KAPOSI'S SARCOMA
0.49%
1/204
0.00%
0/204
0.00%
0/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG NEOPLASM MALIGNANT
0.00%
0/204
0.49%
1/204
0.00%
0/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTASES TO LUNG
0.00%
0/204
0.00%
0/204
0.49%
1/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTASES TO PERITONEUM
0.00%
0/204
0.00%
0/204
0.49%
1/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTASES TO SPINE
0.49%
1/204
0.00%
0/204
0.00%
0/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NON-SMALL CELL LUNG CANCER STAGE IV
0.49%
1/204
0.00%
0/204
0.00%
0/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PROSTATE CANCER
0.49%
1/204
0.00%
0/204
0.49%
1/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RENAL CELL CARCINOMA
0.49%
1/204
0.00%
0/204
0.00%
0/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA
0.49%
1/204
0.49%
1/204
0.00%
0/206
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA OF LUNG
0.49%
1/204
0.49%
1/204
0.00%
0/206
Nervous system disorders
BRAIN OEDEMA
0.00%
0/204
0.98%
2/204
0.00%
0/206
Nervous system disorders
CEREBRAL ISCHAEMIA
0.49%
1/204
0.00%
0/204
0.00%
0/206
Nervous system disorders
SUBARACHNOID HAEMORRHAGE
0.00%
0/204
0.49%
1/204
0.00%
0/206
Nervous system disorders
TRANSIENT ISCHAEMIC ATTACK
0.49%
1/204
0.49%
1/204
0.00%
0/206
Psychiatric disorders
PANIC ATTACK
0.00%
0/204
0.00%
0/204
0.49%
1/206
Psychiatric disorders
SUICIDE ATTEMPT
0.49%
1/204
0.00%
0/204
0.00%
0/206
Renal and urinary disorders
RENAL FAILURE ACUTE
0.49%
1/204
0.00%
0/204
0.00%
0/206
Renal and urinary disorders
RENAL IMPAIRMENT
0.00%
0/204
0.49%
1/204
0.00%
0/206
Reproductive system and breast disorders
BENIGN PROSTATIC HYPERPLASIA
0.00%
0/204
0.00%
0/204
0.49%
1/206
Respiratory, thoracic and mediastinal disorders
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
3.9%
8/204
2.5%
5/204
4.9%
10/206
Respiratory, thoracic and mediastinal disorders
HAEMOTHORAX
0.49%
1/204
0.00%
0/204
0.00%
0/206
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
0.49%
1/204
0.00%
0/204
0.00%
0/206
Respiratory, thoracic and mediastinal disorders
PNEUMONIA ASPIRATION
0.00%
0/204
0.00%
0/204
0.49%
1/206
Respiratory, thoracic and mediastinal disorders
PULMONARY MASS
0.49%
1/204
0.00%
0/204
0.00%
0/206
Respiratory, thoracic and mediastinal disorders
RESPIRATORY FAILURE
0.00%
0/204
0.00%
0/204
0.49%
1/206
Vascular disorders
AORTIC DISSECTION
0.49%
1/204
0.00%
0/204
0.49%
1/206
Vascular disorders
HAEMATOMA
0.00%
0/204
0.49%
1/204
0.00%
0/206
Vascular disorders
HYPOTENSION
0.49%
1/204
0.00%
0/204
0.00%
0/206

Other adverse events

Other adverse events
Measure
QVA149 27.5/12.5 ug Bid
n=204 participants at risk
QVA149 27.5/25 ug Bid
n=204 participants at risk
QAB75
n=206 participants at risk
QVA149 27.5/25 μg capsules
Gastrointestinal disorders
CONSTIPATION
0.49%
1/204
1.5%
3/204
0.49%
1/206
Gastrointestinal disorders
DIARRHOEA
2.5%
5/204
0.98%
2/204
1.5%
3/206
Gastrointestinal disorders
GASTROOESOPHAGEAL REFLUX DISEASE
2.0%
4/204
0.00%
0/204
0.00%
0/206
Gastrointestinal disorders
NAUSEA
0.98%
2/204
2.0%
4/204
0.49%
1/206
Gastrointestinal disorders
TOOTHACHE
0.00%
0/204
2.5%
5/204
1.9%
4/206
Gastrointestinal disorders
VOMITING
1.5%
3/204
0.98%
2/204
0.00%
0/206
General disorders
NON-CARDIAC CHEST PAIN
0.00%
0/204
2.0%
4/204
1.9%
4/206
General disorders
OEDEMA PERIPHERAL
0.49%
1/204
2.9%
6/204
2.4%
5/206
General disorders
PYREXIA
1.5%
3/204
2.0%
4/204
0.00%
0/206
Infections and infestations
BRONCHITIS
0.98%
2/204
3.4%
7/204
3.9%
8/206
Infections and infestations
INFLUENZA
0.49%
1/204
0.98%
2/204
1.9%
4/206
Infections and infestations
LOWER RESPIRATORY TRACT INFECTION
3.9%
8/204
2.0%
4/204
2.9%
6/206
Infections and infestations
NASOPHARYNGITIS
9.3%
19/204
8.8%
18/204
10.7%
22/206
Infections and infestations
PHARYNGITIS
1.5%
3/204
0.00%
0/204
1.5%
3/206
Infections and infestations
PNEUMONIA
2.5%
5/204
1.5%
3/204
0.49%
1/206
Infections and infestations
RESPIRATORY TRACT INFECTION VIRAL
1.5%
3/204
0.98%
2/204
2.9%
6/206
Infections and infestations
RHINITIS
2.0%
4/204
1.5%
3/204
0.97%
2/206
Infections and infestations
SINUSITIS
2.5%
5/204
3.4%
7/204
2.9%
6/206
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
4.9%
10/204
4.9%
10/204
4.4%
9/206
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION BACTERIAL
4.9%
10/204
6.9%
14/204
6.3%
13/206
Infections and infestations
URINARY TRACT INFECTION
0.00%
0/204
2.0%
4/204
1.5%
3/206
Infections and infestations
VIRAL UPPER RESPIRATORY TRACT INFECTION
3.4%
7/204
2.9%
6/204
3.4%
7/206
Injury, poisoning and procedural complications
CONTUSION
1.5%
3/204
0.98%
2/204
0.49%
1/206
Metabolism and nutrition disorders
HYPERGLYCAEMIA
1.5%
3/204
0.00%
0/204
0.49%
1/206
Musculoskeletal and connective tissue disorders
ARTHRALGIA
0.98%
2/204
2.5%
5/204
1.5%
3/206
Musculoskeletal and connective tissue disorders
BACK PAIN
4.9%
10/204
3.4%
7/204
2.4%
5/206
Musculoskeletal and connective tissue disorders
MUSCLE SPASMS
0.49%
1/204
2.0%
4/204
0.49%
1/206
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL PAIN
0.00%
0/204
1.5%
3/204
0.49%
1/206
Musculoskeletal and connective tissue disorders
PAIN IN EXTREMITY
1.5%
3/204
0.49%
1/204
0.97%
2/206
Nervous system disorders
HEADACHE
2.5%
5/204
3.4%
7/204
1.9%
4/206
Psychiatric disorders
INSOMNIA
1.5%
3/204
0.98%
2/204
0.49%
1/206
Respiratory, thoracic and mediastinal disorders
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
34.3%
70/204
31.4%
64/204
34.5%
71/206
Respiratory, thoracic and mediastinal disorders
COUGH
1.5%
3/204
6.4%
13/204
3.4%
7/206
Respiratory, thoracic and mediastinal disorders
DYSPNOEA
0.49%
1/204
1.5%
3/204
2.9%
6/206
Respiratory, thoracic and mediastinal disorders
NASAL CONGESTION
0.00%
0/204
0.49%
1/204
1.9%
4/206
Respiratory, thoracic and mediastinal disorders
OROPHARYNGEAL PAIN
2.0%
4/204
2.5%
5/204
1.5%
3/206
Respiratory, thoracic and mediastinal disorders
PRODUCTIVE COUGH
0.49%
1/204
1.5%
3/204
0.97%
2/206
Skin and subcutaneous tissue disorders
PRURITUS
1.5%
3/204
0.00%
0/204
0.00%
0/206
Skin and subcutaneous tissue disorders
SKIN LESION
1.5%
3/204
0.00%
0/204
0.00%
0/206
Vascular disorders
HYPERTENSION
2.5%
5/204
4.9%
10/204
1.9%
4/206
Vascular disorders
HYPOTENSION
0.00%
0/204
1.5%
3/204
0.00%
0/206

Additional Information

Study Director

Novartis Pharmaceuticals

Phone: 862-778-8300

Results disclosure agreements

  • Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.
  • Publication restrictions are in place

Restriction type: OTHER